Pfizer Inc. PFE
Analyst Consensus
Price Objectif
Analyst historical
| Analyst | Entreprise | Price during analysis | Target price | Potential gain | Publication date |
|---|---|---|---|---|---|
| Michael Yee | UBS | 26.345 $ | 27 $ | 0.66 % | 27/05/2026 |
| Alexandria Hammond | Wolfe Research | 25.96 $ | 26 $ | 0.04 % | 14/05/2026 |
| Terence Flynn | Morgan Stanley | 27.055 $ | 27 $ | -0.05 % | 17/03/2026 |
| Evan David Seigerman | BMO Capital | 26.485 $ | 30 $ | 3.52 % | 09/03/2026 |
| Trung Huynh | RBC Capital | 27.14 $ | 25 $ | -2.14 % | 24/02/2026 |
| Emily Field | Barclays | 26.86 $ | 25 $ | -1.86 % | 19/02/2026 |
| Narumi Nakagiri | Daiwa | 27.73 $ | 27 $ | -0.73 % | 12/02/2026 |
| Alexandria Hammond | Wolfe Research | 25.53 $ | 24 $ | -1.53 % | 17/12/2025 |
| Rajesh Kumar | HSBC | 25.33 $ | 29 $ | 3.67 % | 10/12/2025 |
| Asad Haider | Goldman Sachs | 24.225 $ | 26 $ | 1.78 % | 05/11/2025 |
| Courtney Breen | Bernstein | 24.4481 $ | 30 $ | 5.55 % | 31/10/2025 |
| Tim Anderson | UBS | 27.16 $ | 28 $ | 0.84 % | 01/10/2025 |
| Carter Gould | Cantor Fitzgerald | 22.53 $ | 24 $ | 1.47 % | 22/04/2025 |
| Robyn Karnauskas | Truist Financial | 25.89 $ | 32 $ | 6.11 % | 18/12/2024 |
| Chris Shibutani | Goldman Sachs | 28.46 $ | 33 $ | 4.54 % | 30/10/2024 |
| Courtney Breen | Bernstein | 29.67 $ | 32 $ | 2.33 % | 17/10/2024 |
| Carter Gould | Barclays | 28.93 $ | 32 $ | 3.07 % | 25/09/2024 |
| Narumi Nakagiri | Daiwa | 28.85 $ | 34 $ | 5.15 % | 07/08/2024 |
| Mohit Bansal | Wells Fargo | 31.39 $ | 30 $ | -1.39 % | 31/07/2024 |
| Chris Shibutani | Goldman Sachs | 31.39 $ | 34 $ | 2.61 % | 31/07/2024 |
| Vamil Divan | Guggenheim | 30.72 $ | 36 $ | 5.28 % | 30/07/2024 |
| Carter Gould | Barclays | 27.72 $ | 30 $ | 2.28 % | 10/07/2024 |
| Evan Seigerman | BMO Capital | 29.6 $ | 36 $ | 6.40 % | 22/05/2024 |
| Louise Chen | Cantor Fitzgerald | 26.97 $ | 45 $ | 18.03 % | 14/02/2024 |
| Thomas Yeh | Morgan Stanley | 26.925 $ | 20 $ | -6.93 % | 14/12/2023 |
| Terence Flynn | Morgan Stanley | 30.5 $ | 37 $ | 6.50 % | 27/11/2023 |
| Chris Shibutani | Goldman Sachs | 53.37 $ | 60 $ | 6.63 % | 13/12/2022 |
| David Risinger | Leerink Partners | 52.88 $ | 55 $ | 2.12 % | 23/05/2022 |
| Mohit Bansal | Wells Fargo | 19.11 $ | 141.39 $ | 122.28 % | 10/05/2022 |
| Mohit Bansal | Wells Fargo | 49.04 $ | 55 $ | 5.96 % | 09/05/2022 |
| Vamil Divan | Mizuho Securities | 49.07 $ | 55 $ | 5.93 % | 02/05/2022 |
| Louise Chen | Cantor Fitzgerald | 53.12 $ | 75 $ | 21.88 % | 16/04/2022 |
| Terrance Flynn | Morgan Stanley | 55.17 $ | 55 $ | -0.17 % | 10/04/2022 |
| Andrew Baum | Citigroup | 55.17 $ | 57 $ | 1.83 % | 09/04/2022 |
| Geoff Meacham | Bank of America Securities | 50.27 $ | 70 $ | 19.73 % | 12/03/2022 |
| Chris Schott | J.P. Morgan | 51.7 $ | 57 $ | 5.30 % | 08/02/2022 |
| Carter Gould | Barclays | 51.7 $ | 54 $ | 2.30 % | 08/02/2022 |
| Chris Shibutani | Goldman Sachs | 51.7 $ | 50 $ | -1.70 % | 08/02/2022 |
| Evan Seigerman | BMO Capital | 54.950001 $ | 76 $ | 21.05 % | 15/01/2022 |
| Aaron Gal | Bernstein | 56.22 $ | 65 $ | 8.78 % | 03/01/2022 |
| Geoff Porges | Leerink Partners | 59.1 $ | 56 $ | -3.10 % | 22/12/2021 |
| Colin Bristow | UBS | 54.78 $ | 60 $ | 5.22 % | 13/12/2021 |
| Tobias Gottschalt | Independent Research | 49.8 $ | 54 $ | 4.20 % | 11/11/2021 |
| Tim Anderson | Wolfe Research | 44.09 $ | 46 $ | 1.91 % | 03/11/2021 |
| Daniel Busby | RBC Capital | 42.1 $ | 44 $ | 1.90 % | 29/07/2021 |
| David Toung | Argus Research | 37.54 $ | 55 $ | 17.46 % | 01/06/2021 |